HUTCHMED (China) Limited in 1 story
The narratives 0013.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
0013.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
HUTCHMED validated the China-to-global model by developing fruquintinib in China and licensing ex-China rights to Takeda, which has launched the oncology drug internationally.
Bear side
0 storiesNo bear-side stories for 0013.HK yet.